{"id":"W2737389832","doi":"10.1016/s1470-2045(17)30469-2","title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1863,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"European Society for Medical Oncology","keywords":"Olaparib; Medicine; BRCA mutation; Ovarian cancer; Internal medicine; Oncology; Placebo; PARP inhibitor; Clinical endpoint; Population; Randomized controlled trial; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001239456,0.001576358,0.003857015,0.0004692595,0.0004052796,0.001203483,0.001050745,0.002072104,0.005457962],"category_scores_gemma":[0.001461497,0.0007361307,0.001620888,0.0005165866,0.001183337,0.001447535,0.0003967291,0.003305672,0.001127722],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004913835,"about_ca_system_score_gemma":0.0006703214,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006364763,"about_ca_topic_score_gemma":0.001300518,"domain_scores_codex":[0.9995677,0.000210682,0.00003058339,0.00009420187,0.00003203859,0.0000647472],"domain_scores_gemma":[0.9992898,0.000233242,0.0001350925,0.00005843966,0.00003503199,0.0002484407],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9766582,0.002404445,0.0003454743,0.0007508692,0.0006095035,0.00004274384,0.00004469023,0.0002192743,0.002060042,0.00007428463,0.0007083566,0.01608212],"study_design_scores_gemma":[0.9659812,0.0317253,0.0009189216,0.00003299423,0.0002171959,0.00003794597,0.00001675386,0.0002665651,0.0002026142,0.0001147373,0.0004722469,0.00001345903],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9747771,0.01521659,0.0009407399,0.001065148,0.0008130848,0.002624808,0.001505517,0.000298187,0.002758751],"genre_scores_gemma":[0.9829664,0.006303541,0.00143255,0.00148421,0.0005121696,0.002032467,0.001457764,0.00004359632,0.003767189],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005457962,"threshold_uncertainty_score":0.01825869,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05211112076256093,"score_gpt":0.3733703096465478,"score_spread":0.3212591888839869,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}